BioMarin Pharmaceuticals BMRN Total enzyme product revenues — Revenue
Discontinued — last reported Q4 '23
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BioMarin Pharmaceuticals’s 10-K, filed February 26, 2024, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's total enzyme product revenues — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's total enzyme product revenues — revenue?
- BioMarin Pharmaceuticals (BMRN) reported total enzyme product revenues — revenue of $448.03M in Q4 2023.
- How has BioMarin Pharmaceuticals's total enzyme product revenues — revenue changed year-over-year?
- BioMarin Pharmaceuticals's total enzyme product revenues — revenue increased by 10.6% year-over-year, from $405.09M to $448.03M.
- What is the long-term trend for BioMarin Pharmaceuticals's total enzyme product revenues — revenue?
- Over 2 years (2021 to 2023), BioMarin Pharmaceuticals's total enzyme product revenues — revenue has grown at a 7.3% compound annual growth rate (CAGR), from $1.49B to $1.72B.
- What does total enzyme product revenues — revenue mean?
- The total revenue earned from selling the company's portfolio of enzyme replacement therapy products.
- How do you interpret total enzyme product revenues — revenue?
- An increase indicates successful market adoption, expanded patient access, or improved pricing power for the enzyme therapy portfolio, while a decrease may signal increased competition, patent expirations, or shifts in treatment paradigms.
- How does total enzyme product revenues — revenue compare across companies?
- Comparable to specialized product line revenues in other biotechnology firms focused on rare diseases or orphan drugs, where consistent growth in established franchises funds R&D for new pipeline assets.